ライフサイエンスコーパス: initial presentation

1 ce rate for ABS was 11.4% over 4 years after initial presentation.

2 remained free of tumor for 5 years after the initial presentation.

3 ity to or with the same localizations as the initial presentation.

4 P) had been considered in all three cases at initial presentation.

5 tion who had cTnI assay drawn at the time of initial presentation.

6 8%) completed a questionnaire 3 months after initial presentation.

7 patients had positive CMV IgG serologies at initial presentation.

8 ed a simplified fast-track screen for use at initial presentation.

9 lood specimens obtained from all patients at initial presentation.

10 ity vasculitis on the basis of the patients' initial presentation.

11 ay in resuscitation, or laboratory values on initial presentation.

12 s, leukemia cutis, or meningeal leukemia) at initial presentation.

13 atient with angiographically-confirmed PE at initial presentation.

14 ropriately evaluated and managed after their initial presentation.

15 sually affected the same organ systems as on initial presentation.

16 morrhagic and nonhemorrhagic groups based on initial presentation.

17 odies (ANA) and ANA subsets were obtained at initial presentation.

18 ve disease persisting more than 90 days from initial presentation.

19 peat ED visits and hospital admissions after initial presentation.

20 penia, and hyponatremia were often absent at initial presentation.

21 after stabilization and again 30 days after initial presentation.

22 ecurrence are linked to the primary tumor at initial presentation.

23 pathogen-related differences in symptoms at initial presentation.

24 rological symptoms have been described after initial presentation.

25 ies were obtained 3 months and 4 years after initial presentation.

26 efined epitopes approximately 2 months after initial presentation.

27 d for device activation within 90 minutes of initial presentation.

28 least one definite CCM and 134 were alive at initial presentation.

29 collected and easily obtained at the time of initial presentation.

30 farther from the reference point during its initial presentation.

31 time of phlebotomy, on average 4 hours from initial presentation.

32 e stimulus that had lasted longer during its initial presentation.

33 nd recurrent ACS were assessed 30 days after initial presentation.

34 l discriminations for repeated compared with initial presentations.

35 gnostic uncertainty at the time of patients' initial presentations.

36 At initial presentation, 25% of patients (12% N1, 11% N2, a

37 52%] female) aged 2 to 18 years (mean age at initial presentation, 28 months; range, 0-121 months) we

38 37.5%, P = 0.061), have liver failure at the initial presentation (37.8% versus 9.3%, P = 0.001), and

39 Upon initial presentation, a full periodontal examination was

40 vided to sepsis and septic shock patients at initial presentation and 2) determine the association be

41 (TCR) repertoire in aplastic anemia (AA) at initial presentation and after immunosuppression using a

42 therapy (ECT) on two separate occasions: on initial presentation and again a year later when the pat

43 Twenty-four patients were asked at initial presentation and at 30 days to grade their sever

44 pharmacological treatment decisions both at initial presentation and at follow up.

45 gH CDRII region was identical at the time of initial presentation and at relapse suggesting that clon

46 potency of these responses in patients upon initial presentation and before treatment, we determined

47 ion and level of evidence in the approach to initial presentation and diagnosis of NSTE-ACS, risk ass

48 ed scenes that were attended both during the initial presentation and during repetition.

49 is of anterior uveitis within 90 days before initial presentation and had follow-up visits thereafter

50 asciitis is often confused for cellulitis at initial presentation and is considered to be more severe

51 come of the consecutive NAION event based on initial presentation and to compare mean visual loss of

52 collected and analyzed information regarding initial presentations and final outcomes in patients dia

53 as to analyze the characteristic features of initial presentations and final outcomes of PPLA caused

54 centage of questions answered correctly upon initial presentation) and completion scores (percentage

55 d conditions, complicated biliary disease on initial presentation, and initial presentation to the em

56 psies of test cohorts was performed at their initial presentation, and those spontaneously eliminatin

57 ith AIH, have more aggressive disease at the initial presentation, are less likely to respond to conv

58 Patients were identified according to initial presentation as having localized or multicentric

59 istologic examination and wound culture from initial presentation as well as clinical follow-up docum

60 osed with definite IE within the 12 weeks of initial presentation based on modified Duke criteria.

61 Endotoxemia was not evident on initial presentation, but developed subsequently in 75%

62 Initial presentation can be asymptomatic; however, many

63 Several clinical variables at the time of initial presentation can predict the future risk of deta

64 in patients with lacrimal involvement as the initial presentation, can be difficult because of nonspe

65 e weakness (50%) and muscle atrophy (67%) at initial presentation compared with antisynthetase-positi

66 t an immunodeficiency with a clinically mild initial presentation could be a combined immunodeficienc

67 Analysis of serum from initial presentation demonstrated biphasic hemolysis, co

68 tients, 13 (26%) were correctly diagnosed at initial presentation; diagnosis was delayed, on average,

69 At the time of initial presentation, DNA from patients with CLL was pol

70 record review (length of symptoms; times of initial presentation, emergency department (ED) triage,

71 ht, gestational age at birth, bicarbonate at initial presentation, feeding type, preoperative duratio

72 pect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endo

73 f clinically recorded neutrophil counts with initial presentation for a range of CVDs.

74 .2%) underwent appendectomy within 1 year of initial presentation for appendicitis.

75 Patients with typical AD and non-amnesic initial presentation had a significantly higher ratio of

76 ion of that shape, regardless of whether its initial presentation had been supraliminal or subliminal

77 and severity of heart failure at the time of initial presentation have been formally categorized by t

78 These variations in initial presentation have important clinical consequence

79 Thirteen days after initial presentation, he became febrile and had signs of

80 d as quiescence of disease within 90 days of initial presentation, HZO recurrence was defined as any

81 silent or masked choroid, and a mean age at initial presentation in the third decade.

82 Psychiatric symptoms are prominent in the initial presentation in these cases.

83 Their initial presentation is acute, with a few days to weeks

84 es, along with a high degree of suspicion on initial presentation is crucial in order to provide the

85 cess but the detection of CTC at the time of initial presentation is not necessarily a poor prognosti

86 proliferation caused by its multifocality at initial presentation, lack of aneuploidy, and spontaneou

87 ection of the primary sites months after the initial presentation, light microscopy, and comprehensiv

88 festations may develop many months after the initial presentation, mandating the need for long-term f

89 On initial presentation, men were a decade older (61 vs 50

90 At the initial presentation, NICCD patients had higher levels o

91 f a pre-existing neurological condition, the initial presentation of a non-pregnancy-related problem,

92 basis of nonischemic FFR in patients with an initial presentation of ACS is associated with significa

93 Immunologic priming (initial presentation of an antigen to allow antibody res

94 Rheumatic manifestations may often be the initial presentation of an endocrine disorder.

95 compared cumulative incidence curves for the initial presentation of cardiovascular disease and used

96 fluid samples collected from children during initial presentation of central nervous system inflammat

97 sentation of rheumatic manifestations is the initial presentation of endocrine disease.

98 The initial presentation of hypertension during pregnancy in

99 ated encounters included healthy children at initial presentation of illness.

100 litis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transve

101 In this article, a patient whose initial presentation of lymphoma was the sudden onset of

102 ses without intestinal manifestations as the initial presentation of NSAID-induced colitis.

103 time between exposure to gadolinium and the initial presentation of NSF is typically weeks to months

104 Increased concentrations of BNP at initial presentation of patients with STEMI are associat

105 We conclude that the initial presentation of sarcoidosis is related to sex, r

106 autoimmune diseases are characterized by the initial presentation of the disease being the most sever

107 without neurological involvement) either as initial presentation of the disease or as relapse are un

108 symptoms are not only common, but may be the initial presentation of this systemic inflammatory proce

109 asmatic tuberculomas were not present at the initial presentation of tuberculosis and appeared on bra

110 The majority of initial presentations of CVD are neither myocardial infa

111 Initial presentations of novel song (but not tones or no

112 ht the need for psychiatrists to be aware of initial presentations of paraneoplastic disorders.

113 Although the initial presentations of PPLA caused by different pathog

114 Working groups focused on initial presentation, ongoing management, and empiric an

115 Results Recommendations related to initial presentation, ongoing management, and empirical

116 obtained from 28 patients with ES or PNET at initial presentation or at relapse.

117 tudied, 36 (22%) had TE disease confirmed at initial presentation (PE = 19; DVT only = 17), and four

118 tation (when available), patient symptoms at initial presentation, physical examination findings, ana

119 Eighteen months post initial presentation ptosis and eye movements returned n

120 Recommendations were made related to initial presentation (risk stratification, initial evalu

121 Five athletes (7.2%) considered normal on initial presentation subsequently expressed pathology du

122 rmal, 16 patients; LOH, 2 patients) as their initial presentation, suggesting, albeit with a small pa

123 One month after initial presentation, symptoms worsened.

124 At initial presentation, the median CTG expansion size was

125 Among patients with haemorrhage at initial presentation, the risk of haemorrhage fell from

126 presentation without abrupt or any pain, and initial presentation to a nontertiary care hospital (all

127 Clinical information extended from initial presentation to death.

128 were offered a full 28-day course of PEP at initial presentation to healthcare, with fewer refusals

129 evere injuries is positively associated with initial presentation to high-volume trauma hospitals.

130 ents with systemic vasculitis increased from initial presentation to last observation by a median sco

131 Median interval from initial presentation to LR was 85 months.

132 The mean interval from initial presentation to onset of vitiligo was 77 months

133 sted, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics.

134 biliary disease on initial presentation, and initial presentation to the emergency department.

135 aracteristics that were readily available at initial presentation to the emergency department.

136 ately based on the ophthalmic examination on initial presentation to the hospital.

137 e, ranging from 6/7.5 to light perception on initial presentation to the oncology service.

138 s with chronic lymphocytic leukemia (CLL) at initial presentation to University of Texas M.D. Anderso

139 astatic) were unrelated to clinical stage at initial presentation, treatment history, or histopatholo

140 f DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent org

141 tance Best corrected visual acuity (BCVA) at initial presentation was 0.36 +/- 0.29logMAR and at last

142 the adjusted hazard ratio for haemorrhage at initial presentation was 13.9 (95% CI 2.6-73.8; p=0.002)

143 al visit, a high degree of vitreous cells at initial presentation was associated with a lower inciden

144 The initial presentation was more severe than in known types

145 Initial presentation was treated with steroids (n = 30;

146 ermore, different potentials recorded during initial presentations were indicative of perceptual lear

147 Initial presentations were most commonly either musculos

148 Within 6 months of initial presentation with a necrotizing ulcerative gingi

149 reated aortic segments is precipitated by an initial presentation with AAD.

150 uidelines suggest 12 months of DAPT after an initial presentation with ACS.

151 blast cells from 104 consecutive children at initial presentation with acute lymphoblastic leukemia (

152 The initial presentation with erythema nodosum and periarthr

153 Furthermore, initial presentation with heart failure may be a good pr

154 acco use [1.40 (1.18-1.66)]; and complicated initial presentation with obstruction [1.33 (1.06-1.65)]

155 Given the early onset of symptoms and the initial presentation with pulmonary embolism in some fam

156 ive protein (hs-CRP), for risk assessment at initial presentation with ST-segment elevation myocardia